menu
    • menu
    [{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Bill & Melinda Gates Foundation | Department of Health and Social Care, UK | Biomedical Advanced Research and Development Authority | Wellcome Trust | German Federal Ministry of Education and Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Bill & Melinda Gates Foundation | Department of Health and Social Care, UK | Biomedical Advanced Research and Development Authority | Wellcome Trust | German Federal Ministry of Education and Research","highestDevelopmentStatusID":"7","companyTruncated":"SNIPR Biome \/ Bill & Melinda Gates Foundation | Department of Health and Social Care, UK | Biomedical Advanced Research and Development Authority | Wellcome Trust | German Federal Ministry of Education and Research"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Biomedical Advanced Research and Development Authority | Wellcome Trust","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Biomedical Advanced Research and Development Authority | Wellcome Trust","highestDevelopmentStatusID":"7","companyTruncated":"SNIPR Biome \/ Biomedical Advanced Research and Development Authority | Wellcome Trust"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SNIPR Biome \/ Undisclosed"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SNIPR Biome \/ Undisclosed"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SNIPR Biome \/ Undisclosed"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2024","type":"Funding","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SNIPR Biome","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ CARB-X","highestDevelopmentStatusID":"7","companyTruncated":"SNIPR Biome \/ CARB-X"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SNIPR Biome \/ Undisclosed"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SNIPR Biome \/ Undisclosed"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SNIPR Biome \/ Undisclosed"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2025","type":"Series B Financing","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SNIPR Biome","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"SNIPR Biome \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SNIPR Biome \/ Bill & Melinda Gates Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by SNIPR Biome

    Menu

    SNIPR Biome

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cystic Fibrosis Foundation

                            Deal Size : $40.6 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            SNIPR BIOME Raises EUR 35 Million Series B Financing to Advance CRISPR-Medicines

                            Details : This funding will support the further the clinical development of the company’s CRISPR-based product, SNIPR001, in patients with hematologic cancer, including the ongoing phase 1b trial.

                            Product Name : SNIPR001

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            August 07, 2025

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cystic Fibrosis Foundation

                            Deal Size : $40.6 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SNIPR Biome

                            Denmark arrow
                            ACI Convention
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Bill & Melinda Gates Foundation | Department of Health and Social Care, UK | Biomedical Advanced Research and Development Authority | Wellcome Trust | German Federal Ministry of Education and Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Ora...

                            Details : SNIPR001 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Escherichia coli Infections.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            April 22, 2025

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Bill & Melinda Gates Foundation | Department of Health and Social Care, UK | Biomedical Advanced Research and Development Authority | Wellcome Trust | German Federal Ministry of Education and Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            SNIPR Biome Receives Funding for CRISPR-Medicines to Improve EED in Pregnant Women

                            Details : The funding from the Bill & Melinda Gates Foundation will be used to develop a microbiome-directed intervention designed to improve EED by reducing gut entero-pathogen burden in pregnant women.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 28, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : CARB-X

                            Deal Size : $5.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            SNIPR Biome Receives CARB-X Funding to Advance SNIPR001 in Haematological Cancers

                            Details : Funding supports SNIPR Biome’s CRISPR-medicine SNIPR001, undergoing early-stage trials for E. coli bloodstream infections in patients with hematological cancers.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : CARB-X

                            Deal Size : $5.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Reports Positive Clinical Interim Results for Groundbreaking, First-in-Human, CRISPR-based Microbi...

                            Details : SNIPR001 is a novel, first-in-human, CRISPR-based microbial gene therapy, developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            May 31, 2023

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Further Strengthens CRISPR/Cas IP Portfolio With Patent Grant

                            Details : SNIPR’s CRISPR technology provides a highly selective way to target individual bacterial strains for killing which can be useful for the prevention and treatment of any indication where a specific bacterial strain is the underlying cause of a disease.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            December 22, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryote...

                            Details : SNIPR001, is the first orally dosed CRISPR-based therapeutic candidate and CRISPR-armed bacteriophage cocktail that targets antibiotic-resistant E. coli infections in hematological cancer patients.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            October 03, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage

                            Details : SNIPR001, a CRISPR-armed bacteriophage cocktail that targets the prevention of antibiotic-resistant E. coli infections in hematological cancer patients.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            August 02, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001

                            Details : The experimental CRISPR therapeutic, SNIPR001, is designed to selectively target and eradicate E. coli in the gut, thus preventing translocation of these bacteria to the bloodstream, in a high-risk population of hematological cancer patients at risk for ...

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            April 20, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Biomedical Advanced Research and Development Authority | Wellcome Trust

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 ...

                            Details : SNIPR001 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Escherichia coli Infections.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            March 14, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Biomedical Advanced Research and Development Authority | Wellcome Trust

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth